Pharmaceutical Technology

DECEMBER 7, 2022

Health Canada has granted approval for a supplement to a New Drug Submission (sNDS) of Novavax ’s Covid-19 vaccine (Recombinant protein, Adjuvanted), Nuvaxovid (NVX-CoV2373), for use in adolescents aged 12 to 17 years. The trial is designed to analyse the safety and effectiveness of the vaccine.

Vaccination 264

Vaccination Vaccine Protein Clinical Trials 264

Pharmaceutical Technology

JULY 15, 2022

Health Canada has granted approval for the usage of Moderna’s messenger RNA (mRNA) Covid-19 vaccine, Spikevax, in a 25µg two-dose regimen for active immunisation to prevent Covid-19 in children aged six months to five years. So far, children aged below five years were not eligible to receive the Covid-19 vaccine in Canada.

Vaccination 264

Vaccination Vaccine Gene Therapy Antibody 264

Pharmaceutical Technology

APRIL 11, 2023

The US government is reportedly investing more than $5bn in a programme to accelerate the development of new Covid-19 vaccines and treatments. Health experts have lent their support to the new programme as the existing vaccines may not be as effective against future virus threats.

Vaccination 264

Vaccination Vaccine Development Antibody 264

Fierce Pharma

NOVEMBER 10, 2022

AstraZeneca withdraws US COVID vaccine application, shifts focus to antibody treatments. Thu, 11/10/2022 - 09:02.

Antibody 145

Antibody Vaccination Vaccine 145

Bio Pharma Dive

SEPTEMBER 29, 2020

The world's attention will be on the FDA as it considers initial data from coronavirus vaccine developers. But several other important drugs, including a CAR-T therapy and an Ebola antibody, will also be on the agency's agenda.

FDA Approval 354

FDA Approval Antibody Vaccination Vaccine 354

Bio Pharma Dive

NOVEMBER 8, 2022

A reformulated booster aimed at an earlier omicron subvariant outperformed Novavax’s current vaccine, but a bivalent version did not significantly raise antibody levels.

Antibody 327

Antibody Trials Vaccination Vaccine 327

Bio Pharma Dive

NOVEMBER 4, 2022

Follow-up data show the omicron-adapted shot boosted antibodies against the variant in older adults by more than the companies’ original version.

Antibody 299

Antibody Vaccination Vaccine 299

Pharmaceutical Technology

JUNE 24, 2022

As regulatory agencies gear up for another round of Covid-19 vaccine deliberations centered on emerging variants, Moderna has released data on its booster’s efficacy against Omicron subvariants. 1 variant, on 22 June, Moderna said its booster also showed a “potent” antibody response against Omicron subvariants BA.4

Vaccination 264

Vaccination Vaccine Antibody Medicine 264

Pharmaceutical Technology

JUNE 20, 2023

The World Health Organisation (WHO) has granted an emergency use listing (EUL) to SK bioscience’s Covid-19 vaccine, SKYCovione. SKYCovione is a self-assembled nanoparticle vaccine and the 12th Covid-19 vaccine to receive a EUL from the regulator.

Vaccination 363

Vaccination Vaccine Protein Clinical Trials 363

Pharmaceutical Technology

AUGUST 15, 2022

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional authorisation for Moderna ’s Covid-19 booster vaccine, mRNA-1273.214 (Spikevax Bivalent Original/Omicron), for use in adults aged 18 years and above. It comprises mRNA-1273 (Spikevax) and a vaccine candidate that acts on the SARS-CoV-2 virus’ BA.1

Vaccination 214

Vaccination Vaccine Immune Response Clinical Trials 214

Pharmaceutical Technology

SEPTEMBER 15, 2022

Last year was a positive year for biopharmaceutical companies, particularly those with Covid-19 vaccines. As a result of huge global sales of mRNA Covid-19 vaccines, the split in profits between Pfizer and BioNTech’s Comirnaty contributed towards revenues of $81.3bn and $22.4bn last year, respectively. YoY revenue growth.

Vaccination 272

Vaccination Vaccine Sales Generic Drugs 272

pharmaphorum

JANUARY 21, 2022

A third dose of vaccine has been shown to effectively neutralise the Omicron variant of covid-19, according to researchers. Research led by UCLH, UCL and the Francis Crick Institute found that the booster dose successfully stimulates antibody levels that neutralise Omicron. Overall, antibody levels were nearly 2.5

Antibody 115

Antibody Vaccination Vaccine Genotype 115

BioSpace

AUGUST 31, 2021

Belgium researchers compared the Moderna and Pfizer-BioNTech COVID-19 vaccines and found that the Moderna jabs generated twice the antibodies than the Pfizer-BioNTech vaccine.

Antibody 109

Antibody Vaccination Vaccine Research 109

World of DTC Marketing

APRIL 11, 2021

QUICK THOUGHT: People believe the COVID-19 vaccine was developed in less than a year but that’s not true. Based on the virus a number of vaccines targeting the spike protein were designed, tested in animal models and found to be quite promising against SARS and other coronavirus illnesses like Middle East respiratory syndrome.

Vaccine 303

Vaccine Vaccination Clinical Trials Clinical Trials 303

Pharmaceutical Technology

MARCH 31, 2023

The European Medicines Agency (EMA) has recommended HIPRA’s Covid-19 vaccine , Bimervax, as a Covid-19 booster. Available to people ages 16 years and above who have been vaccinated with a Covid-19 mRNA vaccine, EMA’s Human Medicines Committee concluded the vaccine is ready for marketing authorization in the EU, on 30 March.

Vaccination 277

Vaccination Vaccine Immune Response Antibody 277

Pharmaceutical Technology

FEBRUARY 1, 2023

RSV researchers at major pharmaceutical companies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind.

Vaccination 162

Vaccination Vaccine Antibody Development 162

BioSpace

AUGUST 11, 2020

Although the world is eagerly awaiting news of an effective and safe vaccine against COVID-19, several companies are moving ahead testing therapeutic antibodies against the disease.

Antibody 128

Antibody Vaccination Vaccine 128

Medical Xpress

DECEMBER 6, 2022

Nearly three years into the pandemic, many of us now carry antibodies against the virus—due to an infection or two, a few doses of mRNA vaccine, or a round of monoclonal-antibody treatment.

Antibody 98

Antibody Vaccination Vaccine Immune Response 98

Bio Pharma Dive

JUNE 20, 2023

The shot, which the Danish company acquired from Emergent BioSolutions, spurred protective antibodies against the mosquito-borne virus in older adults.

Antibody 211

Antibody Vaccination Vaccine 211

pharmaphorum

JULY 6, 2021

Nina Garrett, R&D director at Abingdon Health discusses the key role antibody testing is playing in the pandemic and how an integrated approach with vaccines could help normal life resume. This is where antibody tests come in. Neutralising Antibodies. ” .

Antibody 111

Antibody Immune Response Protein Vaccine 111

pharmaphorum

DECEMBER 9, 2021

AstraZeneca’s antibody cocktail for COVID-19, now called Evushield, has become the first drug in the class to be authorised for prevention of infection by the US FDA. The emergency use authorisation (EUA) for Evushield activates a 700,000 order for the antibody from the US government, worth upwards of $726 million.

Antibody 124

Antibody Immune Response Vaccine Vaccination 124

BioSpace

OCTOBER 11, 2020

government program to advance COVID-19 vaccines and therapeutics, for a monoclonal antibody cocktail. AstraZeneca signed a deal with Operation Warp Speed, the U.S.

Antibody 123

Antibody Vaccination Vaccine 123

Pharmaceutical Technology

SEPTEMBER 19, 2022

Additionally, in the trial, the antibody cocktail was found to be well-tolerated. Evusheld is a cocktail of two long-acting antibodies, tixagevimab and cilgavimab. These antibodies are obtained from B-cells of convalescent Covid-19 patients. 5 variant, the company noted.

In-Vitro 279

In-Vitro Antibody Vaccine Vaccination 279

pharmaphorum

AUGUST 12, 2022

Half a million people in the UK with conditions like blood cancer that prevents them being protected from COVID-19 vaccines are facing another winter shielding, because the government has shelved plans to offer treatment with AstraZeneca’s antibody therapy Evusheld. — Kidney Care UK (@kidneycareuk) August 12, 2022.

Antibody 145

Antibody Vaccination Vaccine Drugs 145

Pharmaceutical Technology

OCTOBER 17, 2024

Bavarian Nordic’s MVA-BN vaccine showed equivalent antibody response and safety between teenagers and adults in an NIH study.

Vaccination 130

Vaccination Vaccine Antibody 130

Pharma Times

OCTOBER 7, 2021

AstraZeneca has submitted an emergency approval to the US drug regulators for its COVID-19 antibody cocktail, which would be the first non-vaccine protection from the virus to be granted approval.

Antibody 121

Antibody Regulation Vaccination Vaccine 121

Bio Pharma Dive

OCTOBER 25, 2024

Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped during the third quarter.

Sales 173

Sales Vaccination Vaccine Antibody 173

pharmaphorum

SEPTEMBER 17, 2020

Eli Lilly has followed up supportive data from its Olumiant in COVID-19 with results of a study showing its antibody treatment could help prevent hospitalisation from the disease. The double-blind placebo-controlled antibody study involved patients with symptoms outside hospitals, who were treated with four different dose strengths.

Antibody 129

Antibody RNA Trials Clinical Trials 129

pharmaphorum

JUNE 15, 2021

The delta variant of COVID-19 may be holding back the lifting of lockdown restrictions in the UK, but there is some good news – the AstraZeneca/Oxford University vaccine seems to offer a high level of protection against it. Antibody flunks post-exposure prevention study.

Antibody 119

Antibody Clinical Trials Clinical Trials Trials 119

STAT News

SEPTEMBER 3, 2022

A new study is raising concerns about the effectiveness of the monkeypox vaccine being used in the United States and other parts of the world. Read the rest…

Vaccination 122

Vaccination Vaccine Antibody 122

Medical Xpress

MAY 11, 2023

The new mRNA vaccines have just as good a protective effect against COVID-19 for the very oldest as for younger people. However, the study shows that elderly people with a low antibody response after vaccination were at increased risk of dying from the omicron variants of the disease.

Antibody 98

Antibody Vaccination Vaccine Research 98

Pharmaceutical Technology

APRIL 10, 2023

It will also be used for the treatment of people who are not likely to have an adequate immune response to Covid-19 vaccination or for people who are not recommended for Covid-19 vaccination. Evusheld (formerly AZD7442) is a combination of two long-acting antibodies, tixagevimab (AZD8895) and cilgavimab (AZD1061).

Immune Response 264

Immune Response Antibody Vaccine Vaccination 264

Pharmaceutical Technology

OCTOBER 19, 2022

Syncromune and Biocytogen Pharmaceuticals’ wholly owned subsidiary Eucure Biopharma have entered an exclusive global licence agreement for OX40 antibody YH002 and two other active ingredients. . This technology aims to create a custom-made autologous cancer vaccine utilising the cancer antigens of the patient.

Antibody 130

Antibody Licensing Licensing Containment 130

BioPharma Reporter

JANUARY 17, 2022

Vir Biotechnology and the Bill & Melinda Gates Foundation have partnered up to develop broadly neutralizing antibodies designed to provide a âvaccinal effectâ for the treatment of HIV and prevention of malaria.

Antibody 127

Antibody Development Vaccination Vaccine 127

Fierce Pharma

JULY 18, 2023

After bagging a highly anticipated FDA nod Monday, Sanofi and AstraZeneca’s respiratory syncytial virus (RSV) antibody now has a date on a committee's calendar to determine its place in U.S. The panel has set a date for Aug. 3 to evaluate the new drug.

Antibody 98

Antibody Vaccination Vaccine FDA Approval 98

BioSpace

AUGUST 13, 2020

A COVID-19 vaccine candidate developed by Chinese pharmaceutical company Sinopharm triggered antibody-based immune responses in early and mid-stage trials.

Immune Response 132

Immune Response Vaccination Vaccine Antibody 132

pharmaphorum

JULY 18, 2022

MBA, managing director at CanSino Biologics Europe, tells us about Convidecia, a single dose SARS-CoV-2 vaccine offered as an injectable and inhalant that allows ease of storage, an alternative option for individuals with needle phobias, and robust elongated CD4 and CD8 cellular response. Morgon, PharmD, LL.M, How it works.

Vaccination 138

Vaccination Vaccine Development Immune Response 138